CAB-LA PrEP Prescriptions and Abandonment in the United States, January 2022–June 2025
Clinical Infectious Diseases · 12.11.2026
DOI: 10.1093/cid/ciag721 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 12.11.2026. Verfasst von Weiming Zhu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta GA,….
Abstract (Originalsprache)
Background
Injectable long-acting cabotegravir (CAB-LA) for HIV preexposure prophylaxis (PrEP) was approved by the US Food and Drug Administration in 2021. A national assessment of CAB-LA PrEP abandonment, defined as not filling any prescription, could inform national PrEP implementation efforts.
Methods
We conducted a national observational cohort study using IQVIA Longitudinal Prescription data to characterize persons prescribed CAB-LA or daily oral PrEP (DO-PrEP) in the United States during January 2022–June 2025. We compared 6-month abandonment risk among individuals with an index CAB-LA or DO-PrEP prescription during 2022–2024. Associations were estimated using multivariable modified Poisson regression models and reported as adjusted risk ratios (aRRs) with 95% confidence intervals (CIs).
Results
The number of individuals prescribed CAB-LA PrEP increased from 4,645 in 2022 to 23,378 in 2024 and 25,018 during January–June 2025. The proportion of individuals receiving CAB-LA increased from 0.1% in quarter 1 of 2022 to 5.4% in quarter 2 of 2025. While women had a higher 6-month PrEP abandonment risk than men, regardless of PrEP regimen, they were less likely to abandon CAB-LA (11.9%) than DO-PrEP (18.1%, aRR=0.68, 95% CI: 0.62–0.74). The opposite was observed for men, with men more likely to abandon CAB-LA PrEP (10.2%) than DO-PrEP (8.1%, aRR=1.25, 95% CI: 1.20–1.31).
Conclusions
CAB-LA PrEP prescribing increased steadily during the first 3.5 years after approval; abandonment risk differed by PrEP regimen and sex. Addressing barriers to injectable and daily oral PrEP uptake, and strengthening sex-specific PrEP implementation strategies, may further reduce abandonment risk.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of HIV Prevention, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta GA, USA.
ORCID-Profile: Weiming Zhu, Rupa R Patel, Nicole L Davis, Athena P Kourtis
Zitieren
APA
Zhu, W., Patel, R. R., Huang, Y. A., Davis, N. L., Hoover, K. W., & Kourtis, A. P. (2026). CAB-LA PrEP Prescriptions and Abandonment in the United States, January 2022–June 2025. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciag721
Vancouver
Zhu W, Patel RR, Huang YA, Davis NL, Hoover KW, Kourtis AP. CAB-LA PrEP Prescriptions and Abandonment in the United States, January 2022–June 2025. Clinical Infectious Diseases. 2026. doi:10.1093/cid/ciag721
BibTeX
@article{Zhu2026,
author = {Zhu, Weiming and Patel, Rupa R and Huang, Ya-Lin A and Davis, Nicole L and Hoover, Karen W and Kourtis, Athena P},
title = {CAB-LA PrEP Prescriptions and Abandonment in the United States, January 2022–June 2025},
journal = {Clinical Infectious Diseases},
year = {2026},
doi = {10.1093/cid/ciag721}
}
EUVIMED